Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Several reasons have been proposed as explanations why so many S. aureus vaccines have failed in clinical trials. Clearly, the organism has a battery of virulence factors which may require a multipronged approach and neutralizing just a single mechanism with a specific mAb may not suffice.
The WHO just released the latest statistics on what has turned into the largest ever outbreak of Ebola virus (EBOV) in Africa. The epidemic started in Guinea around December 2013. As of 7/27/2014, Guinea, Liberia, Nigeria, and Sierra Leone have reported a total of 1323 cases, with 729 fatalities [i]. Most Continue reading Ebola – Fact Sheet (Updated 10/3/2014)
There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature, and how this all matters in clinical practice, on the Continue reading What is the “Niche” for Ceftolozane / Tazobactam?